Coya Therapeutics (COYA) Enterprise Value (2022 - 2026)

Coya Therapeutics has disclosed Enterprise Value across 5 years of filings, most recently posting $94.0 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 41.68% year-over-year to $94.0 million; the TTM figure through Jun 2026 stood at $94.0 million (up 41.68% YoY), while the FY2025 annual figure was $50.2 million, down 12.51% from the prior year.
• Enterprise Value came in at $94.0 million for Q2 2026 at Coya Therapeutics, up from $41.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $109.0 million in Q1 2024 to a low of $6.3 million in Q4 2022.
• Average Enterprise Value over 5 years is $53.9 million, with a median of $55.6 million recorded in 2024.
• Year-over-year, Enterprise Value surged 572.92% in 2023 and tumbled 42.63% in 2026.
• Over 5 years, Enterprise Value stood at $6.3 million in 2022, then surged by 572.92% to $42.7 million in 2023, then jumped by 34.45% to $57.4 million in 2024, then slipped by 12.51% to $50.2 million in 2025, then soared by 87.26% to $94.0 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $94.0 million in Q2 2026, $41.7 million in Q1 2026, and $50.2 million in Q4 2025.